Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL trial of rifaximin + lactulose prophylaxis after TIPS
NL-OMON59413Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatic encephalopathy (HE) comparing Rifaximin + lactulose prophylaxis with Placebo (2 arms). Primary endpoint: Development of overt hepatic encephalopathy within 3 months after TIPS. Started Mar 2026; status: recruiting.
02
Drugs
rifaximinlactulose
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NL-OMON59413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59413.